License and Collaboration Agreements (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | |
|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2026 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront and milestone payment | $ 29.0 | ||
| Terminated Pre Clinical Program | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront and milestone payment | 25.0 | ||
| MediLink Therapeutics | DLL3-Targeting ADC | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Milestone fee | $ 8.0 | ||
| Maximum additional milestone payments | $ 584.0 | 584.0 | |
| Pfizer | Tisotumab Vedotin | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Milestone fee | 10.0 | ||
| Maximum additional milestone payments | $ 248.0 | $ 248.0 | |